Stoquity Living researchResearch LedgerSlicesMethodologyFor institutionsAbout
Stoquity Research Ledger

Glaukos Corporation (GKOS)

NYSE: GKOS · Surgical & Medical Instruments & Apparatus · Aliso Viejo, CA

Our rating: Positive

Call changed from Neutral to Positive at $242.48, moderate conviction, October 29, 2026.

Breaks if: Revenue growth decelerates to below 15% YoY in either of the next two quarterly prints, or trailing-twelve-month free cash flow worsens past -$75M by the end of calendar 2027 — either condition would signal that the operating-leverage story is not developing as the valuation prices in, and would warrant revisiting the call toward Neutral.

Key figures

Market value$14.0B
Revenue, last 12 months$690M
Net income, last 12 months−$170M
Free cash flow, last 12 months$36M
Price to earningsn/a
Free cash flow yield0.3%
Dividend yield0.0%
Operating margin−25.5%
Return on equity−22.8%
Beta to the S&P 5001.23
Volatility, annualized53.3%

Reported quarters

Quarter endingRevenueYear on yearEarnings per shareFree cash flow
September 30, 2026$211M58.0%$0.03$36M
June 30, 2026$186M49.5%$-0.31$12M
March 31, 2026$151M41.2%$-0.34−$16M
December 31, 2025$143M35.7%$-2.33$4M
September 30, 2025$134M38.1%$-0.28−$12M
June 30, 2025$124M29.7%$-0.34$6M
March 31, 2025$107M24.6%$-0.32−$20M
December 31, 2024$105M28.1%$-0.59−$1M

Three-model forecasts for the next quarter

Written November 21, 2026, before the report. Each settles from the SEC filing.

15 ledger entries and 23 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.